Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company...
Day: February 14, 2023
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment,...
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
Radiopharm Theranostics Initiates Process for Nasdaq Listing
Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late...
Nanox.AI Connects to Nuance Precision Imaging Network to Improve Early Detection of Chronic Diseases with Workflow-Integrated AI
The secure nationwide AI-powered cloud platform streamlines care team communication and delivers patient-specific imaging insights within clinical workflowsNEVE ILAN, Israel,...
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
Intense interest in PharmAla’s best-in-class manufacturing and regulatory excellence continues as PharmAla examines further Australian opportunitiesVANCOUVER, British Columbia, Feb. 14,...
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
Live event scheduled for Friday, February 24th at 11:00 am Eastern TimeIRVINE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- AEON...
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023...
Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA Recently issued U.S. patent expands PRL-02...
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ to be available in May 2023TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”)...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
Quipt Home Medical Reports Record First Quarter Fiscal 2023 Financial Results Posting Positive Net Income, Revenue Growth of 38% and Adjusted EBITDA Growth of 50%
Posts Strong Adjusted EBITDA Margin of 22% and Sequential Organic Growth of 2%CINCINNATI, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Quipt...
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy Cord blood-derived T-Cell Receptor...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
-- NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid...
Monopar Announces Camsirubicin Clinical Program Update – Improved Side Effect Profile Seen to Date Compared to Doxorubicin
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December...
Breckenridge Distillery Strikes Gold at 2023 World Whiskies Awards
The World's Highest Distillery Earns Three Top Prizes for This Year's World Whiskies Awards for Best American Blended Malt, Best...